Viking Therapeutics Newsroom

Will weight loss drugs be included in the US medical insurance, becoming the strongest "roadblock" for the Trump team?

The "Dual Weight Loss Champions" led the significant rise.

Gelonghui Finance20:45 ET

BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125

Moomoo News17:31 ET · Ratings

Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline

MT Newswires16:00 ET

H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102

Moomoo News12:32 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target

Benzinga11:47 ET

Viking Therapeutics' VK2735: A Leading Contender in Obesity Treatment With Strong Performance and Safety Profile

TipRanks11:45 ET

Press Release: Viking Mergers & Acquisitions Announces Key Promotions in Florida Division, Showcasing Internal Growth-Focused Culture and Leadership

Dow Jones11:34 ET

Viking Mergers & Acquisitions Announces Key Promotions in Florida Division, Showcasing Internal Growth-Focused Culture and Leadership

PR Newswire11:33 ET

Amgen (AMGN.US) released mid-term data on the weight loss therapy MariTide, showing weight loss effects comparable to Novo Nordisk.

Amgen announced on Tuesday that its experimental weight loss therapy MariTide achieved significant results in Phase 2 trials.

Zhitong FinanceNov 26 08:38 ET

White House Proposes Big Expansion of Medicare, Medicaid Coverage of Obesity Drugs

WSJNov 26 05:37 ET

Positive Phase 2 Trial Results Drive Viking Therapeutics (VKTX) Stock Upwards

TipRanksNov 25 05:16 ET

Trump Nominates Marty Makary For FDA Commissioner

Barron'sNov 22 22:27 ET

Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report?

Yahoo FinanceNov 22 11:31 ET

How Is The Market Feeling About Viking Therapeutics?

BenzingaNov 22 11:15 ET

Viking Therapeutics Analyst Ratings

BenzingaNov 22 08:24 ET · Ratings

B.Riley Financial Initiates Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $109

Moomoo NewsNov 21 20:32 ET · Ratings

Viking Therapeutics: Strong Potential in Obesity and Type 2 Diabetes Market With Innovative VK2735 Program

TipRanksNov 21 20:15 ET

Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs

Analyst UpgradesNov 20 13:26 ET

Viking Therapeutics Is More Than Just a Weight-loss Stock, and That's Drawing Cheers

MarketWatchNov 20 12:06 ET

Express News | Viking Therapeutics Shares Rise 4.6% Premarket After Co Presents Detailed Mid-Stage Data for Experimental Liver Disease Drug

ReutersNov 20 05:06 ET